DGAP-News: Evotec AG / Key word(s): Miscellaneous
EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES
07.11.2018 / 14:58
The issuer is solely responsible for the content of this announcement.
Hamburg, Germany, 07 November 2018:
Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its management will be presenting and attending the following upcoming conferences:
Jefferies London Healthcare Conference 2018, London, UK
Date: Wednesday, 14 November, to Thursday, 15 November 2018, Presentation: 14 November 2018, 11.20 am GMT (06.20 am EST, 12.20 pm CET)
Webcast: Click here for the webcast
Venue: London, UK
Attendee: Dr Werner Lanthaler, Chief Executive Officer
15th Kempen London Conference, London, UK
Date: Wednesday, 21 November 2018
Venue: London, UK
Attendee: Dr Werner Lanthaler, Chief Executive Officer
German Equity Forum 2018, Frankfurt am Main, Germany
Date: Monday, 26 November, to Tuesday, 27 November 2018, Presentation: 26 November 2018, 04.00 pm CET (10.00 am EST, 03.00 pm GMT)
Venue: Frankfurt am Main, Germany
Attendee: Enno Spillner, Chief Financial Officer
16th Berenberg European Conference, Surrey, UK
Date: Wednesday, 05 December 2018, Presentation: 05 December 2018, 09.45 am GMT (04.45 am EST, 10.45 am CET)
Venue: Surrey, UK
Attendee: Dr Werner Lanthaler, Chief Executive Officer
About Evotec AG Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,400 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @EvotecAG.
FORWARD LOOKING STATEMENTS Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
07.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language:
English
Company:
Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone:
+49 (0)40 560 81-0
Fax:
+49 (0)40 560 81-222
E-mail:
info@evotec.com
Internet:
www.evotec.com
ISIN:
DE0005664809
WKN:
566480
Indices:
MDAX, TecDAX
Listed:
Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women's health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
EVOTEC SE 
